WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) who have received prior systemic therapies, including an EGFR-directed therapy. The Food and Drug Administration (FDA) grants Priority Review to

NASSAU, Bahamas–(BUSINESS WIRE)–OneSpaWorld Holdings Limited, (NASDAQ: OSW), the pre-eminent global provider of health and wellness products and services on board cruise ships and in destination resorts around the world, today is providing preliminary revenue and Adjusted EBITDA expectations for Fiscal Year 2024 and introducing select Fiscal Year 2025 guidance. The Company is providing this update ahead of investor meetings and its fireside chat presentation at the ICR Conference 2025. Leonar

NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132.00 per share in cash for a total equity value

OKLAHOMA CITY & TORRANCE, Calif.–(BUSINESS WIRE)–This new collaboration provides a scalable, integrated solution for developing and manufacturing complex peptide drugs efficiently.

VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven benefits of the enVista® platfor

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)—- $MD–Pediatrix Announces Strategic Initiatives For
Enhanced Shareholder Value Creation

BOSTON & NEW HAVEN, Conn.–(BUSINESS WIRE)–Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The financing was co-led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer Ventures and YK Bioventures, as well as existing investors Canaan Partners, Sanofi Ventures, Taiho Ventures, Osage Venture Partners, HongShan Capital Group, and Connecticut Innovation

SAN DIEGO–(BUSINESS WIRE)—- $REVB #GEMINI–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franc

SAN DIEGO–(BUSINESS WIRE)– #biobam–BioBam, a leading bioinformatics solutions provider, proudly presents OmicsBox Version 3.4 at the San Diego Plant and Animal Genome Conference (PAG 32). This latest release introduces a range of enhancements designed to address the evolving needs of modern genomics and transcriptomics research. A key highlight of OmicsBox 3.4 is the integration of CellKB, a robust cell-type prediction tool for single-cell RNA sequencing (scRNA-Seq) analysis. CellKB streamlines scRNA-

HANGZHOU, China–(BUSINESS WIRE)–Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases